ESLAW — Estrella Immunopharma Inc.
NASDAQ · Healthcare · Biotechnology
$0.08
+$0.00 (+3.33%)
Estrella Immunopharma Inc. (ESLAW) is a biotechnology company listed on NASDAQ. It is led by Cheng Liu Ph.D., based in 5858 Horton Street, EmeryVille, CA, United States, 94608. Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Net income was -$4.8M.
Use this ESLAW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ESLAW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ESLAW SEC filings page. Lician reads the product cache first so this HTML stays unique to Estrella Immunopharma Inc. even when a live quote feed is slow.
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
ESLAW Key Statistics
Market Cap
$0.00M
Volume
2,183
Previous Close
$0.07
Day Range
$0.07 – $0.08
EPS
-$0.27
Revenue
$0.00
Net Income
-$7.31M
Gross Profit
$0.00
Free Cash Flow
$0.00
ESLAW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.31M | -$11.11M | -$996.10K |
| EPS (Diluted) | -$0.27 | -$36.35 | $0.00 |
Total Assets
$4.45M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.17M
Operating Cash Flow
-$16.07M
Free Cash Flow
$0.00
Estrella Immunopharma Inc. Company Information
- CEO, President & Director
- Cheng Liu Ph.D.
- Headquarters
- 5858 Horton Street, EmeryVille, CA, United States, 94608
- Website
- www.estrellabio.com
- Phone
- 510 318 9098
- IPO / Founded
- 2021-09-14
- Sector
- Healthcare
- Industry
- Biotechnology